Zenbexus Capsule
NDC Package 0003-5710-21

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Zenbexus (iberdomide) capsules is zENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time [see Clinical Studies (14)]. This formulation utilizes a capsule delivery system. Marketed by E.r. Squibb & Sons, L.l.c., this product is identified by NDC 0003-5710 and is authorized under FDA application NDA221075.

Identification & Billing

NDC Package Code
0003-5710-21
Package Description
21 CAPSULE in 1 BOTTLE
Product Code
0003-5710
11-Digit Billing Format
00003571021
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Zenbexus
Non-Proprietary Name
Iberdomide
Substance Name
Iberdomide Hydrochloride
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
IBERDOMIDE HYDROCHLORIDE 1 mg/1
Usage Information
ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Regulatory & Marketing

Labeler Name
E.r. Squibb & Sons, L.l.c.
Product Type
Human Prescription Drug
FDA Application #
NDA221075
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-13-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0003-5710-21 identifies a specific commercial package of 21 capsule in 1 bottle of Zenbexus, a human prescription drug labeled by E.r. Squibb & Sons, L.l.c.. This capsule is formulated for oral use and contains iberdomide hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by E.r. Squibb & Sons, L.l.c. on August 13, 2026. The current certification is valid through December 31, 2027.

How is this E.r. Squibb & Sons, L.l.c. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00003571021. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0003-5710-21
11-Digit CMS (5-4-2)
00003-5710-21

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.